---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-025464"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:57:42.501963+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology reports positive Phase 1 topline data for LYMPHIR + pembrolizumab in gynecologic cancers

## Summary
- 24% objective response rate (ORR) and 48% clinical benefit rate (CBR) among 21 evaluable patients.
- No unexpected safety signals or serious immune-related adverse events observed in 25 evaluable patients.
- Investigator-initiated trial by University of Pittsburgh; full results expected at upcoming international cancer conference.
- Study evaluated LYMPHIR (denileukin diftitox-cxdl) + pembrolizumab in relapsed/refractory ovarian and endometrial cancers.

## SEC filing metadata
- accession: 0001213900-26-025464
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390026025464/0001213900-26-025464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390026025464/ea0280663-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-025464
- JSON: https://secwatch.observer/filing/0001213900-26-025464.json
- Plain text: https://secwatch.observer/filing/0001213900-26-025464.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.